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CD341 CELLS FROM POOR MOBILIZERS ARE QUALITATIVELY EQUIVA-
LENT TO CD341 CELLS FROM GOOD MOBILIZERS
Jiang, L.1, Malik, S.1, Litzow, M.2, Gastineau, D.2, Micallef, I.2,
Roy, V.3, Solberg, L.3, Zubair, A.C.1 1Mayo Clinic, Jacksonville, FL;
2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL
Marrow damage from chemo- and radiation therapy can lead to
poor CD341 cell mobilization. Such therapies have also been sug-
gested to affect quality of CD341 cells. We tested the hypothesis
that CD341 cells from low mobilizers are qualitatively inferior to
CD341 cells from high mobilizers.
CD341 cell quality was defined by proportion of primitive
CD341 cell subsets (CD341CD38-, CD341HLA-DR- and
CD341 in G0 stage of cell cycle), the proportion of CD341 cells
that express CXCR4 and CD26 homing proteins and days to neutro-
phil and platelet engraftments post transplant. CD341 cell content
and CD34 subsets analyses were performed using flow cytometry.
Cell cycle analysis was performed using simultaneous staining of
DNA (Hoechst) and RNA (Pyronin Y) to distinguish CD341 cells
in G0, G1 and S/M phases of cell cycle.
Weevaluated theCD341 cell quantityandqualityof139autologous
filgrastimmobilized HPC products collected between 2004 and 2007.
The median patient age was 58 years and 60% were males. Patients
were diagnosed with plasma cell dyscrasia, or non-Hodgkin’s lym-
phoma. The median CD341 cell/kg was 4.9  106 and median time
to neutrophil and platelet engraftmentwas 12 and 18 days respectively.
Patients were grouped into low, moderate and high mobilizers if
their total CD341 cell collection was # 3  106/kg, . 3 106/kg
and\5106/kg, and$ 5 106/Kg respectively. The median num-
ber of primitive stem cells increases with increasing CD341 cell
numbers and this association was statistically significant (p 5
0.001). However, when the ratios of the primitive CD34 subsets to
total CD341 cell counts were compared among the mobilization
groups, the ratios were not significantly different. Co-expression of
neither CD26 nor CXCR4 homing proteins with CD34 antigen cor-
related with CD341 cell mobilization.
Table 1. CD34+ cell subsets and mobilization capacity
Mobilization (median  106/Kg)CD34+ subsets Low Moderate High p valueN 33 70 36CD34+ 3 4.6 6.6 <0.001CD34+CD38- 1.2 2.6 3.8 <0.001CD34+HLA-DR- 1.1 1.6 2 0.001CD34+CD26+ 0 0 0 0.88CD34+CXCR4+ 0 0 0 0.55CD34+G0 stage 1.5 3.3 4.6 <0.001CD34+ subsets/CD34+ ratioCD34+CD38- 0.52 0.55 0.53 0.41CD34+HLA-DR- 0.30 0.35 0.27 0.84CD34+G0 stage 0.71 0.75 0.64 0.58Evaluation of days to neutrophil engraftment among the mobiliza-
tion groups did not show a statistically significant difference (p 5
0.1). However, days to platelet engraftment among the mobilization
groups was statistically significantly different (p 5 0.05). This find-
ing may not be clinically significant.
In summary, the proportion of primitiveCD341 cells inHPCprod-
ucts anddays toneutrophil engraftmentwerenot influencedbyCD341
cell mobilization capacity. The quality of CD341 cells from low
mobilizerswas comparable toCD341 cells fromhighmobilizers. Prior
therapies may affect the quantity but not the quality of CD341 cells.137
CYCLOPHOSPHAMIDE (CY)/G-CSF CANNOT COMPLETELY OVERCOME
IMID-INDUCED IMPAIRMENT OF PERIPHERAL BLOOD STEM CELL (PBSC)
MOBILIZATION (MOB) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
Osman, S., Kanate, A., Bunner, P., Leadmon, S., Hart, K., Goff, L.,
Tse, W., Cumpston, A., Remick, S., Abraham, J., Craig, M.,
Hamadani, M. West Virginia University Hospitals, Morgantown, WVNovel agents are routinely used as induction therapy for MM, but
there is concern about their impact on PBSC Mob. Some studies
suggest that CY/G-CSF Mob may overcome suppressive effects of
lenalidomide on PBSCMob, however an optimal mobilization strat-
egy for this population remains controversial.
We report here PBSC collection outcomes of 107 consecutive
MM patients, who uniformly underwent Mob with CY (1.5mg/m2)
and G-CSF (10mg/kg/day). 44 patients received older induction
therapies, while 63 received novel agents (including; lenalidomide-
(n5 13), bortezomib- (n 5 15) and IMiD- (n5 49) containing reg-
imens). Mob parameters including, peak peripheral blood (PB)
CD341 count, CD341 cell yield on day1, total CD341 cell yield,
and number of apheresis sessions were analyzed relative to induction
regimens. Mobilization failure was defined as failure to collect$ 2
106 cells/Kg body weight.
The median patient age was 57yrs. The median number of prior
therapies was one, while 29% received prior radiation. Compared to
older regimens, patients receiving novel inductions had lower peak
PB CD341 count (70/uL vs. 47/uL; p 5 0.003), however total
CD341 cell yield (7.6  106 vs. 6.4  106; p 5 0.07), CD341 dose
collected on day 1 (3.9 106 vs 3.1 106 p5 0.20) and total number
of apheresis sessions (2.6 vs 2.2 p 5 0.068) were not significantly dif-
ferent. Lenalidomide containing regimens when compared to all other
regimens (n5 94) revealed a lower peak PB CD341 count (34/uL vs
59/uL; p5 0.03) and higher total number of apheresis sessions (3.3 vs
2.3; p5 0.001). Total CD341 yield (6.8 106 vs 7.1 106 p5 0.78)
and CD341 cells collected on day 1 (2.6 106 vs 3.7 106; p5 0.24)
were not significantly different. IMiDs as a class when compared to
non-IMiD regimens showed significantly lower peak PB CD341
count (45/uL vs 66/uL; p 5 0.004) and higher number of apheresis
sessions (2.7 vs 2.2; p 5 0.004). Total CD341 yield (7.6  106 vs
6.7  106 p 5 0.21) and dose collected on day 1 (3.5  106 vs 3.6 
106; p 5 0.91) were not significantly different. A total of 6 patients
failed mobilization, including 3 who received lenalidomide.
In conclusion our limited retrospective study shows that CY/G-
CSF Mob partially overcomes suppressive effects of lenalidomide
on PBSC mobilization by requiring increased number of apheresis
sessions. Our data also suggest that impairment of PBSCMobmight
be a class-effect of IMiDs, and not merely restricted to lenalidomide,
at least in the context of CY/G-CSF Mob.138
THE EFFECT OF BODY MASS INDEX ON PATIENT MORTALITY AFTER
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
Jones, J.L., Hundley, B.C., Salzman, D.E., Koralkar, R., Vaughan,W.P.
University of Alabama at Birmingham, Birmingham, AL
Background: Elevated body mass index (BMI) is associated with
lifelong risk of medical morbidity and has been implicated as a risk
factor for mortality after hematopoietic stem cell transplantation
HSCT. Previous publications suggest various thresholds for in-
creased mortality. The Center for International Bone Marrow
Transplant Research (CIBMTR) threshold for considering obesity
a significant comorbidity is a BMI greater than 35. A recent publica-
tion using CIBMR data suggested a BMI of 30 was a significant
threshold for morbidity and mortality.
Objective:To further investigate the association of BMI with excess
mortality in a single center analysis, we undertook a survey of 232
consecutive autologous HSCT (aHSCT) patients with myeloma
and non-Hodgkin’s lymphoma.
Patients and Methods: These 232 adult patients studied received
their aHSCT at UAB between November 2006 and September
2010. Height and weight were obtained during the final evaluation
and consent visit just prior to initiation of preparative therapy, ex-
cluding 10 patients with missing one or the other of these variables.
Myeloma patients received melphalan 200mg/ M2 (reduced to
140mg/M2 for age greater than 70 or creatinine clearance \
40mL/min). Non-Hodgkin’s lymphoma (NHL) patients received
intravenous busulfan targeted to a total exposure of 16000mM*min,
cyclophosphamide (5gm/M2) and etoposide (1800 mg/M2). Based
upon the reviewed literature, we defined obesity using three BMI co-
horts: non-obese\35kg/M2, obese5 35-39kg/M2, morbidly obese
Poster Session I S205. 39kg/M2. A more objective secondary analysis divided our pa-
tients’ BMI into quartiles was also used to explore risk threshold.
Results:The median BMI for our entire population was 33.9 (15.6-
57.6). The 100 daymortality in themyeloma andNHLpatients were
4/153 (2.6%) and 2/72 (2.7%), respectively. Using the above litera-
ture driven definitions, the data showed a significantly higher mor-
tality with increasing obesity (p\ 0.0001, see Table).
Table 1. Risk of Mortality by Degree of Obesity
BMI Group Alive Dead TotalTable 1. Characterstic
Da
Age (yrs)
CD34+ stem
cells Infused
3
WBC engraftment day
Platelet engraftment (days)
Neutopenic fever Rate
Stomatitis Rate
Median (range),
*Log-rank test ,
†U tests of study popula
y +3 group (N598) D
60.2 (36,77)
.3106 (2.5108,
1.44 x106)
3
11 (9-15)
12 (8-97)
61 (62.2%)
81 (82.7 %)tion
ay +5 group (N549) p
57.6 (43-74)
.04 x106 (2.8 x108,
1.9 x106)
12 (10-14) <
14 (9-63)
20 (41.7%)
25 (52.1%) <<35kg/m2 114 13 127
35-39 kg/m2 88 0 88
>39 kg/m2 12 5 17
Total 214 18 232p<.0001 (Chi-Square).
In the quartile analysis, there was one death in the lowest quartile, no
deaths in the second quartile, three deaths in the third quartile and
two deaths in the fourth quartile.
Conclusion:Our results mirror what other studies have found; that
increasing obesity is especially significant in a range above 30-35 kg/
M2 based solely on BMI classification. Our quartile analysis appears
to demonstrate a steep slope over our median (33.9kg/M2).
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RETROSPECTIVE COMPARISON OF DAY15 VERSUS DAY13 INITIATION
OF G-CSF IN MULTIPLE MYELOMA PATIENTS RECEIVING AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Koralkar, R., Hundley, B., Donna, S.E., Vaughan, W.P. University of
Alabama at BIrmingham, Birmingham, AL
Background: Filgrastim (G-CSF) administration after autologous
hematopoietic stem cell transplant (aHSCT) is routinely used to
shorten duration of neutropenia and risk of infection. The optimum
post transplant Day for startingG-CSF is not standardized.We have
historically used aHSCTDay13, but others have reported good re-
sults using Day 15.
Methods: Beginning 15 May 2009, patients with multiple myeloma
(MM) transplanted with myeloblative doses of melphalan and an
aHSCT24hours later receivedGCSF(250mg/m2) subcutaneouslydaily
fromDay15 until absolute granulocyte count (AGC) of 2000/mL.We
performed a validation after 49 patients comparing time to engraftment
of platelets and neutrophils compared to the immediately preceding 98
control patients given daily gCSF from Day 13 to the same AGC
endpoint.Additional endpoints includedstomatitis, transfusion support,
incidence of neutropenic fever, length of day, and 30 day mortality.
Results: There was no significant difference in number of CD341
cells infused among the two groups and there was no 30 day mortality
in either group.TheDay13 patients achievedneutrophil engraftment
a median of one day shorter than the Day15 patients (p\0.001, log-
rank). Median time to platelet recovery of more than 50  109/L was
two days earlier in Day 13 Group than Day 15 Group (p 5 0.02 in
log rank test). However, the rate of neutropenic fever rate was signifi-
cantly higher inDay13Group compared toDay15Group (62% vs.
42%, p 5 0.019). The rate of stomatitis was also higher in Day 13
Group compared to Day15 Group (82.7% vs. 52.1%, p5\0.001).Value
0.29†
0.79†
0.001*
0.023*
0.019†
0.001†Conclusion: Day 13 Administration of G-CSF provides early en-
graftment but there is increased rates for fever, stomatitis. The ap-
parent illogic of more neutropenic fever with faster white blood
cell (WBC) engraftment may be explained by better infectious dis-
ease prophylaxis in the more recent group.140
IMPACT OF CD34 CELL DOSE ON PLATELET ENGRAFTMENT AND
PLATELET TRANSFUSIONS FOLLOWING AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Shariatmadar, S.1, Pereira, D.2, Smith, R.2, Goodman, M.2 1University
of Miami Miller School of Medicine/Jackson Memorial Medical Center,
Miami, FL; 2University of Miami Miller School of Medicine/Jackson
Memorial Medical Center, Miami, FL
Introduction: Maximizing the CD34 cell content of the graft has
been reported to lead to faster platelet engraftment and lower
requirement for platelet transfusions in patients undergoing autolo-
gous stem cell transplantation (A-HSCT). We evaluated the impact
of CD34 cell dose on platelet recovery and transfusion requirements
in 114 consecutive adults undergoing A-HSCT with a CD34 cell
dose of . 2  106/kg recipient body weight (BW) infused.
Methods: From January 2007 to March 2010, 114 adults with NHL
(n: 45), multiple myeloma (n: 44), Hodgkin’s disease (n: 23) and AML
(n: 2) underwent apheresis (range: 1-7) and A-HSCT. Patients were
categorized in to 3 groups based on the CD341 cell dose transplanted
[group 1: 2.0-2.99  106 (n: 55), group 2: 3.0-5.0  106 (n: 38) and
group 3: . 5  106 CD34/kg recipient BW (n: 21)]. Neutrophil
and Platelet engraftment (platelet count. 20,000/ul for 2 consecutive
days without platelet support) and transfusion requirements post-
transplant were evaluated and correlated with patient’s age, diagnosis
and number of apheresis.
Results: Median neutrophil engraftment following transplantation
was 11 days in all groups, while median platelet engraftment was 14
days in group 1 and 13 days in groups 2 and 3. Platelet recovery by
days 30 and 60 was 90.7%/96.3% in group 1, 94.7%/100% in group
2, 90.5%/95.2% in group 3. Two patients with NHL in group 1
(3.6%) and one with AML in group 3 (4.8%) were platelet-dependent
. 60 days post-transplantation. One patient withNHL in group 1 ex-
pired on day 6 from transplant-related complications.Median platelet
transfusions were 3 doses of platelets in group 1 and 2 doses in other
groups. Patient’s age, diagnosis and number of apheresis did not affect
30 and 60 day platelet recovery/transfusions post-transplant. Nine pa-
tients (7.9%) received plerixafor-mobilized transplants with median
platelet engraftment 14 days post-transplant.
Conclusion: CD34 cell dose did not significantly impact platelet re-
covery and transfusion requirements post-transplantation with rapid
platelet recovery achievable with CD34 cell dose . 2  106/kg rec
BW. Other factors including the number of platelet precursors in
the transplanted product rather than CD34 cell dose may be a more
important indicator of platelet recovery post-transplantation.141
EFFICACY AND SAFETY OF HEMATOPOIETIC STEM CELL REMOBILIZA-
TION WITH PLERIXAFOR (MOZOBIL) 1 G-CSF IN PATIENTS WITH
GERM CELL TUMOR
Schriber, J.1, Horwitz, M.2, Libby, E.3, Huebner, D.4, Mody, P.D.4,
Holman, P. 1Banner Blood and Marrow Transplant Program, Phoe-
nix, AZ; 2Duke University Medical Center, Durham, NC; 3UNM
Cancer Center, Albuquerque, NM; 4Genzyme Corporation, Cam-
bridge, MA
Autologous hematopoietic stem cell transplantation can be cura-
tive for patients (pts) with germ cell tumors (GCT). Many such pts
are heavily pretreated. Moreover, most protocols call for tandem
transplant requiring higher cell yields. This creates a situation
where many pts are unable to successfully mobilize adequate cells.
Mobilization with plerixafor (P)1 G-CSF (G) is safe and effective
for pts with myeloma and lymphoma. Herein we describe the safety
